Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster lunch

1462 - TLE3 expression and the survival rates of the patients with advanced serous ovarian cancer (50P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Hanna Anishchanka

Citation

Annals of Oncology (2017) 28 (suppl_10): x7-x15. 10.1093/annonc/mdx653

Authors

H. Anishchanka1, S. Shelkovich2

Author affiliations

  • 1 Oncology, Belarusian State Medical University, 220116 - Minsk/BY
  • 2 Oncology, Belarusian Medical. Academy of Postgraduate Education, 220013 - Minsk/BY
More

Resources

Abstract 1462

Background

It was previously shown that transducin-like enhancer of split 3 (TLE3) is associated with outcome in patients with taxane-treated breast cancer and endometrioid ovarian cancer (OC). In the present work we assessed the association between TLE3 expression and survival rates in patients with serous ovarian carcinoma.

Methods

100 patients diagnosed with primary serous advanced EOC, underwent complex therapy in Minsk city oncologic center in 2007-2011. Immunohistochemical staining of TLE3 was performed on tissue obtained from the surgical resection. The tumor was considered TLE3-positive when stained with more than 30% of the nuclei.

Results

5-year overall survival (OS) was 0,480 (95% CI [0,379; 0,609]), the median lifetime – 45,5 months. The progression free survival (PFS) was 0,301 (95% CI [0,220; 0,412]). The TLE3 positive tumors were revealed in 19%. PFS was 0,490 (95% CI [0,287; 0,837] in cases with positive tumors in compare with 0,261 (95% CI [0,179; 0,380]) – in negative tumors (P = 0,023). OS was 0,756 (95% CI [0,574; 0,996]) in TLE3 positive cases and 0,434 (95% CI [0,326; 0,578]) - in negative (P = 0,095). All patients with TLE3 positive tumors underwent platinum based chemotherapy and taxanes. In the group with TLE3 negative tumors both platinum based regimens were used – with taxanes or cyclophosphamide. 5-year PFS was similar in the groups – 0,261 (95% CI [0,172; 0,394]) and 0,250 (95% CI [0,094; 0,666]) (P = 0,070), OS – 0,449 (95% CI [0,331; 0,607]) and 0,400 (95% CI [0,196; 0,818]) (P = 0,248).

Conclusions

Determination of TLE3 expression in the resected tumor is necessary for predicting tumor response to chemotherapy. Positive TLE3 expression can serve as the indication for the inclusion of taxanes in the adjuvant chemotherapy schemes. Negative TLE3 expression is a factor of poor prognosis both when using taxanes, and when using cyclophosphamide. Therefore, treatment of this category of patients should start with second-line regimens.

Clinical trial identification

Legal entity responsible for the study

Belarusian Medical Academy of Postgraduate Education, Department of Oncology

Funding

Belarusian Medical Academy of Postgraduate Education

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings